SPRAVATO Treatment

A New Day Begins With Spravato

SPRAVATO™ demonstrated efficacy in treatment-resistant depression in adults, when administered in conjunction with an oral antidepressant.

The First & Only...

NMDA receptor antagonist approved in conjunction with an oral AD for TRD in adults¹

FDA Approved

IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT (AD) FOR TREATMENT-RESISTANT DEPRESSION (TRD) IN ADULTS¹

The first and only NMDA receptor antagonist approved for TRD in adults

SPRAVATO™ hypothesized mechanism of action

Baseline Psychiatric Patient Characteristics

Studied in more than 1700 adult patients with treatment-resistant depression

Baseline Psychiatric Patient Characteristics

References:​

1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.

2.Data on file. Janssen Pharmaceuticals, Inc. Titusville, NJ.

Indication:
SPRAVATO™ (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults.​

SPRAVATO™ is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO™ as an anesthetic agent have not been established.

‍

For more information on SPRAVATO treatment, call our mental health clinic at 855.4CHARAK